TheraRadar

Pharma Intelligence, Simplified

Landscape → Rare Disease

Sickle Cell Disease

254 clinical trials

104 active
/
254 total (since 2015)
36
Phase 1 Active
88 total
62
Phase 2 Active
130 total
22
Phase 3 Active
56 total
7
Phase 4 Active
22 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Novartis 5 5 1
Vertex Pharmaceuticals Incorporated 4 1 0
Novo Nordisk 3 5 0
Forma Therapeutics, Inc. 3 2 0
Agios Pharmaceuticals, Inc. 3 0 0
Fulcrum Therapeutics 2 2 0
CSL Behring 2 1 0
Sanofi 2 0 0
Pfizer 1 8 11
Theravia 1 3 0
Roche 1 1 0
Genetix Biotherapeutics Inc. 1 1 0
Disc Medicine, Inc 1 0 0
Beam Therapeutics Inc. 1 0 0
Biossil Inc. 1 0 0
NCT07450430 NOT YET RECRUITING
Optimal Timing of Ketamine Initiation for SCD Pain
Boston Children's Hospital n=90
NCT04084080 ACTIVE NOT RECRUITING
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
University of Pittsburgh n=173
NCT05031780 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Agios Pharmaceuticals, Inc. n=286
NCT06439082 RECRUITING
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Novartis Pharmaceuticals n=315
NCT06609226 RECRUITING
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Novo Nordisk A/S n=480
NCT05431088 RECRUITING
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
Pfizer n=389
NCT06612268 RECRUITING
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Novo Nordisk A/S n=408
NCT06975865 RECRUITING
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
Sanofi n=192
NCT03814746 ACTIVE NOT RECRUITING
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
Novartis Pharmaceuticals n=255
NCT07247188 RECRUITING
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Sanofi n=100
NCT07274254 NOT YET RECRUITING
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Nantes University Hospital n=104
NCT04624659 ACTIVE NOT RECRUITING
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Forma Therapeutics, Inc. n=450
NCT05477563 RECRUITING
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Vertex Pharmaceuticals Incorporated n=26
NCT04208529 ENROLLING BY INVITATION
A Long-term Follow-up Study in Participants Who Received CTX001
Vertex Pharmaceuticals Incorporated n=160
NCT05329649 RECRUITING
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Vertex Pharmaceuticals Incorporated n=15
NCT05951205 NOT YET RECRUITING
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype
Vertex Pharmaceuticals Incorporated n=12
NCT06989567 NOT YET RECRUITING
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
Asklepion Pharmaceuticals, LLC n=120
NCT05285917 RECRUITING
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Brown University n=400
NCT06818266 NOT YET RECRUITING
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Assistance Publique - Hôpitaux de Paris n=130
NCT06761560 NOT YET RECRUITING
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
Yves Pastore n=29
NCT04293185 ACTIVE NOT RECRUITING
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
Genetix Biotherapeutics Inc. n=35
NCT05392894 RECRUITING
RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
King's College Hospital NHS Trust n=120
NCT06561061 COMPLETED
Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)
Indiana University n=100
NCT05470998 COMPLETED
L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity
Tanta University n=50
NCT05348915 TERMINATED
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
Pfizer n=242
NCT04935879 COMPLETED
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Pfizer n=241
NCT02813850 COMPLETED
Oxygen Therapy and Pregnancy in Sickle Cell Disease
Assistance Publique - Hôpitaux de Paris n=178
NCT03573882 TERMINATED
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
Pfizer n=179
NCT04188509 TERMINATED
Open-Label Extension of Voxelotor
Pfizer n=162
NCT05084521 COMPLETED
Interest of Famotidine in Children With Sickle Cell Disease
Assistance Publique - Hôpitaux de Paris n=30
NCT03745287 COMPLETED
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Vertex Pharmaceuticals Incorporated n=63
NCT04839354 COMPLETED
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial
Claudia R. Morris n=271
NCT05561140 TERMINATED
Resolution of Sickle Cell Leg Ulcers With Voxelotor
Pfizer n=88
NCT03789591 COMPLETED
Hydroxyurea Optimization Through Precision Study
Lifespan n=104
NCT04218084 TERMINATED
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
Pfizer n=236
NCT05632354 TERMINATED
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
Pfizer n=47
NCT04750707 COMPLETED
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )
Global Health Uganda LTD n=270
NCT05033314 TERMINATED
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
University Health Network, Toronto n=4
NCT05253781 COMPLETED
Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE)
University of Lagos, Nigeria n=476
NCT04927247 TERMINATED
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Pfizer n=72
NCT03704922 COMPLETED
Age of Blood in Sickle Cell Transfusion
University of North Carolina, Chapel Hill n=26
NCT04150757 TERMINATED
Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED
Abigail Nixon n=5
NCT05228834 TERMINATED
Voxelotor Neurocognitive Function Study
Pfizer n=1
NCT04844099 COMPLETED
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
Liverpool School of Tropical Medicine n=723
NCT03036813 COMPLETED
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
Pfizer n=449
NCT03933397 TERMINATED
Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
Duke University n=328
NCT02675790 COMPLETED
Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
Vanderbilt University Medical Center n=120
NCT03615924 TERMINATED
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
AstraZeneca n=193
NCT02433158 TERMINATED
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
GlycoMimetics Incorporated n=154
NCT04301336 COMPLETED
Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
Beni-Suef University n=350
NCT02560935 COMPLETED
Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II
Vanderbilt University Medical Center n=440
NCT04293172 WITHDRAWN
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
AstraZeneca
NCT03417947 COMPLETED
Vitamin D Supplementation in Children With Sickle Cell Disease
St. Justine's Hospital n=42
NCT02179177 TERMINATED
Apixaban in Patients With Sickle Cell Disease
Nirmish Shah n=16
NCT03128515 COMPLETED
Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas
Indiana University n=187
NCT02449616 COMPLETED
Evaluation of Repeat Administration of Purified Poloxamer 188
Mast Therapeutics, Inc. n=16

Data: ClinicalTrials.gov